Clinical Data’s Q2 Sales Jump 27 Percent | GenomeWeb

This article has been corrected from a previous version, which contained factual errors regarding Clinical Data's vilazodone and Stedivaze programs. GenomeWeb regrets this inaccuracy.

NEW YORK (GenomeWeb News) – Clinical Data today reported that its second-quarter revenues increased 27 percent year over year, due to a 51 percent rise in gross sales of its Familion genetic tests, which are sold through the firm’s PGx Health division.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.